CO2019004004A2 - Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico - Google Patents
Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólicoInfo
- Publication number
- CO2019004004A2 CO2019004004A2 CONC2019/0004004A CO2019004004A CO2019004004A2 CO 2019004004 A2 CO2019004004 A2 CO 2019004004A2 CO 2019004004 A CO2019004004 A CO 2019004004A CO 2019004004 A2 CO2019004004 A2 CO 2019004004A2
- Authority
- CO
- Colombia
- Prior art keywords
- treatment
- pharmaceutical composition
- liver disease
- fatty liver
- alcoholic fatty
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title 1
- -1 1,4-benzoxazine compound Chemical class 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona una composición farmacéutica para la profilaxis y el tratamiento de la EHGNA que comprende como un ingrediente activo un compuesto de 1,4-benzoxazina representado por la fórmula (I): o una sal farmacéuticamente aceptable del mismo, y un vehículo farmacéuticamente aceptable, así como un método para la profilaxis y el tratamiento de la EHGNA el cual comprende administrar una cantidad terapéuticamente eficaz del compuesto de 1,4-benzoxazina mencionado anteriormente representado por la fórmula (I) y demás a un paciente en necesidad del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662400200P | 2016-09-27 | 2016-09-27 | |
| PCT/JP2017/034654 WO2018062134A1 (en) | 2016-09-27 | 2017-09-26 | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019004004A2 true CO2019004004A2 (es) | 2019-07-31 |
Family
ID=60083378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0004004A CO2019004004A2 (es) | 2016-09-27 | 2019-04-23 | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11285160B2 (es) |
| EP (1) | EP3518936B1 (es) |
| JP (1) | JP6980008B2 (es) |
| KR (1) | KR20190061027A (es) |
| CN (2) | CN109789147B (es) |
| AU (1) | AU2017338161A1 (es) |
| BR (1) | BR112019005456A2 (es) |
| CA (1) | CA3038247A1 (es) |
| CO (1) | CO2019004004A2 (es) |
| ES (1) | ES2840079T3 (es) |
| IL (1) | IL265292A (es) |
| MX (1) | MX2019003470A (es) |
| PH (1) | PH12019500618A1 (es) |
| RU (1) | RU2019112148A (es) |
| TW (1) | TW201817425A (es) |
| WO (1) | WO2018062134A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102162921B1 (ko) * | 2018-11-28 | 2020-10-07 | 건양대학교 산학협력단 | 니페디핀 함유 나노입자를 포함하는 지방간 질환 및 인슐린 저항성 예방 또는 치료용 조성물 |
| AR117988A1 (es) | 2019-02-05 | 2021-09-08 | Mitsubishi Tanabe Pharma Corp | Medicamento para profilaxis o tratamiento para la fibrosis pulmonar |
| EP4066840A1 (en) * | 2019-11-26 | 2022-10-05 | Mitsubishi Tanabe Pharma Corporation | Prophylactic or therapeutic agent for non-alcoholic steatohepatitis in humans |
| WO2023101441A1 (ko) * | 2021-11-30 | 2023-06-08 | 에스케이케미칼 주식회사 | 마이크로조말 트리글리세라이드 전달 단백질 억제제의 섬유화 질환 치료 용도 |
| CN117379414A (zh) * | 2023-11-09 | 2024-01-12 | 中国人民解放军陆军军医大学第一附属医院 | 盐酸决奈达隆在制备治疗非酒精性脂肪性肝病和胆汁淤积性肝病的药物中的应用 |
| CN118766941B (zh) * | 2024-08-14 | 2025-11-14 | 中国药科大学 | 洛美他派及其组合物在制备治疗肝纤维化的药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100438910C (zh) * | 1999-04-27 | 2008-12-03 | 田边三菱制药株式会社 | 肝脏疾病的预防治疗药 |
| CN101379048B (zh) * | 2006-02-02 | 2012-03-21 | 田边三菱制药株式会社 | 可用作盐皮质激素受体调节试剂的苯并*嗪和相关的含氮杂双环化合物 |
| TWI385161B (zh) | 2006-02-02 | 2013-02-11 | Mitsubishi Tanabe Pharma Corp | 含氮雜雙環化合物 |
| JP5173653B2 (ja) * | 2007-08-01 | 2013-04-03 | 田辺三菱製薬株式会社 | 医薬組成物 |
| US8258131B2 (en) * | 2007-08-01 | 2012-09-04 | Mitsubishi Tanabe Pharma Corporation | Fused bicyclic compound |
| CA2790914A1 (en) * | 2010-03-24 | 2011-09-29 | Dong-A Pharm. Co., Ltd. | Pharmaceutical composition comprising dipeptidyl peptibase-iv inhibitor for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same |
| EP2883870B8 (en) | 2012-08-08 | 2019-01-23 | Mitsubishi Tanabe Pharma Corporation | Method for producing 1,4-benzoxazine compound |
-
2017
- 2017-09-26 US US16/336,667 patent/US11285160B2/en active Active
- 2017-09-26 WO PCT/JP2017/034654 patent/WO2018062134A1/en not_active Ceased
- 2017-09-26 RU RU2019112148A patent/RU2019112148A/ru not_active Application Discontinuation
- 2017-09-26 AU AU2017338161A patent/AU2017338161A1/en not_active Abandoned
- 2017-09-26 MX MX2019003470A patent/MX2019003470A/es unknown
- 2017-09-26 KR KR1020197011752A patent/KR20190061027A/ko not_active Ceased
- 2017-09-26 CN CN201780057969.4A patent/CN109789147B/zh not_active Expired - Fee Related
- 2017-09-26 CA CA3038247A patent/CA3038247A1/en not_active Abandoned
- 2017-09-26 CN CN202210632897.4A patent/CN114984021A/zh active Pending
- 2017-09-26 ES ES17784023T patent/ES2840079T3/es active Active
- 2017-09-26 JP JP2019516546A patent/JP6980008B2/ja not_active Expired - Fee Related
- 2017-09-26 EP EP17784023.8A patent/EP3518936B1/en not_active Not-in-force
- 2017-09-26 BR BR112019005456A patent/BR112019005456A2/pt not_active IP Right Cessation
- 2017-09-26 TW TW106132944A patent/TW201817425A/zh unknown
-
2019
- 2019-03-11 IL IL265292A patent/IL265292A/en unknown
- 2019-03-21 PH PH12019500618A patent/PH12019500618A1/en unknown
- 2019-04-23 CO CONC2019/0004004A patent/CO2019004004A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2840079T3 (es) | 2021-07-06 |
| BR112019005456A2 (pt) | 2019-06-04 |
| RU2019112148A3 (es) | 2021-01-15 |
| TW201817425A (zh) | 2018-05-16 |
| EP3518936B1 (en) | 2020-11-18 |
| KR20190061027A (ko) | 2019-06-04 |
| CN109789147A (zh) | 2019-05-21 |
| JP2019529477A (ja) | 2019-10-17 |
| IL265292A (en) | 2019-05-30 |
| MX2019003470A (es) | 2019-08-29 |
| CA3038247A1 (en) | 2018-04-05 |
| US11285160B2 (en) | 2022-03-29 |
| CN109789147B (zh) | 2022-06-24 |
| RU2019112148A (ru) | 2020-10-29 |
| CN114984021A (zh) | 2022-09-02 |
| AU2017338161A1 (en) | 2019-04-18 |
| PH12019500618A1 (en) | 2019-11-18 |
| WO2018062134A1 (en) | 2018-04-05 |
| US20210290627A1 (en) | 2021-09-23 |
| JP6980008B2 (ja) | 2021-12-15 |
| EP3518936A1 (en) | 2019-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| CL2019003091A1 (es) | Terapia de combinación. | |
| CO2018010748A2 (es) | Agentes antivirales contra la hepatitis b | |
| CO2019000069A2 (es) | Agentes antivirales contra la hepatitis b | |
| MX375417B (es) | Uso de ácido (r)-2-[3-[[n-(benzoxazol-2-il)-n-3-(4-metoxifenoxi)propil]aminometil]fenoxi]butírico o una sal, o solvato del mismo para el tratamiento de la esteatosis hepática no alcohólica, supresión de la deposición de grasa en el hígado, y en la reducción de células de kupffer en el hígado. | |
| CL2020000747A1 (es) | Formulaciones de niraparib. | |
| UY35273A (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn | |
| CO6821938A2 (es) | Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1 | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| UY37998A (es) | Agentes antivirales contra la hepatitis b | |
| CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| MX2018007815A (es) | Tetrahidropiranil amino-pirrolopirimidinona y metodos de uso de la misma. | |
| TN2015000391A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| AR128459A2 (es) | Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación | |
| MX391440B (es) | Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende. | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| MX389553B (es) | Composicion para incrementar la expresion de pgc-1alfa | |
| MX384072B (es) | Compuesto derivado de pirrolo-piridina, metodo para preparar el mismo y composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o el tratamiento de enfermedades relacionadas con la proteina cinasa. | |
| CO2022008616A2 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma | |
| MX2020005006A (es) | Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular. | |
| DOP2019000299A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| DOP2013000004A (es) | Agentes terapeuticos 976 |